Reviewing Large LAMA2 Deletions and Duplications in Congenital MuscularDystrophy Patients by Oliveira, Jorge et al.
  Universidade de São Paulo
 
2014-09-30
 
Reviewing Large LAMA2 Deletions and
Duplications in Congenital MuscularDystrophy
Patients
 
 
Journal of Neuromuscular Diseases, Amsterdam, v.1, n.2, p.169-179, 2014
http://www.producao.usp.br/handle/BDPI/46473
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Genética e Biologia Evolutiva - IB/BIO Artigos e Materiais de Revistas Científicas - IB/BIO
Journal of Neuromuscular Diseases 1 (2014) 169–179
DOI 10.3233/JND-140031
IOS Press
169
Research Report
Reviewing Large LAMA2 Deletions and
Duplications in Congenital Muscular
Dystrophy Patients
Jorge Oliveiraa,e,f , Ana Gonc¸alvesa,f , Ma´rcia E. Oliveiraa,f , Isabel Finezab, Rita C.M. Pavanelloc,
Mariz Vainzofc, Elsa Bronze-da-Rochad, Rosa´rio Santosa,d,f,1,∗ and Ma´rio Sousae,f,1
aUnidade de Gene´tica Molecular, Centro de Gene´tica Me´dica Dr. Jacinto de Magalha˜es, Centro Hospitalar do
Porto, Porto, Portugal
bUnidade de Neuropediatria, Centro de Desenvolvimento da Crianc¸a Luı´s Borges, Hospital Pedia´trico de Coimbra,
Centro Hospitalar Universita´rio de Coimbra, Coimbra, Portugal
cCentro deEstudos doGenomaHumano eCe´lulas Tronco,Departamento deGene´tica eBiologiaEvolutiva, Instituto
de Biocieˆncias, Universidade de Sa˜o Paulo, Sa˜o Paulo, SP, Brasil
dDepartamento de Cieˆncias Biolo´gicas, Laborato´rio de Bioquı´mica, Faculdade de Farma´cia, Universidade do
Porto, Porto, Portugal
eDepartamento de Microscopia, Laborato´rio de Biologia Celular, Instituto de Cieˆncias Biome´dicas Abel Salazar
(ICBAS), Universidade do Porto, Porto, Portugal
fUnidade Multidisciplinar de Investigac¸a˜o Biome´dica-UMIB, Instituto de Cieˆncias Biome´dicas Abel Salazar
(ICBAS), Universidade do Porto, Porto, Portugal
Abstract.
Background: Congenital muscular dystrophy (CMD) type 1A (MDC1A) is caused by recessive mutations in laminin-2
(LAMA2) gene. Laminin-211, a heterotrimeric glycoprotein that contains the 2 chain, is crucial for muscle stability establishing
a bond between the sarcolemma and the extracellular matrix. More than 215 mutations are listed in the locus specific database
(LSDB) for LAMA2 gene (May 2014).
Objective: A limited number of large deletions/duplications have been reported in LAMA2. Our main objective was the identi-
fication of additional large rearrangements in LAMA2 found in CMD patients and a systematic review of cases in the literature
and LSDB.
Methods: In four of the fifty-two patients studied over the last 10 years, only one heterozygous mutation was identified, after
sequencing and screening for a frequent LAMA2 deletion. Initial screening of large mutations was performed by multiplex
ligation-dependent probe application (MLPA). Further characterization implied several techniques: long-range PCR, cDNA and
Southern-blot analysis.
Results: Three novel large deletions in LAMA2 and the first pathogenic large duplication were successfully identified, allowing
a definitive molecular diagnosis, carrier screening and prenatal diagnosis. A total of fifteen deletions and two duplications
previously reported were also reviewed. Two possible mutational “hotspots” for deletions may exist, the first encompassing
exons 3 and 4 and second in the 3’ region (exons 56 to 65) of LAMA2.
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Conclusions: Our findings show that this type of mutation is fairly frequent (18.4% of mutated alleles) and is underestimated
in the literature. It is important to include the screening of large deletions/duplications as part of the genetic diagnosis strategy.
Keywords: LAMA2, congenital muscular dystrophy, large deletion, large duplication, review
INTRODUCTION
LAMA2-related dystrophy (LAMA2-RD) collec-
tively gathers two distinct clinical entities: the classical
phenotype with congenital onset known as MDC1A,
and a milder limb-girdle type muscular dystrophy
with onset during childhood (late-onset or “ambulant”
LAMA2-RD) [reviewed by 1, 2]. As foreseeable by
this designation, these entities are caused by reces-
sive mutations in LAMA2 gene located on chromosome
6q22-23 and spanning 65 exons [3, 4]. This gene
codes for the 2 chain of laminin-211, an extracellular
glycoprotein expressed in the basal membrane of stri-
ated muscles, peripheral nerves, brain and trophoblast
[5–7]. The interaction of laminin-211 with cell-surface
receptors such as -dystroglycan and integrin (mainly
71 in adult skeletal muscle) explains its major rele-
vance in the overall extracellular architecture, integrity
and cell adhesion [reviewed by 8].
MDC1A represents the most frequent form of CMD
in western countries, accounting for 30 to 50% of cases
[9]. Typical clinical features includes severe hypoto-
nia associated with muscle weakness manifesting at
birth or during early infancy, proximal joint contrac-
tures, elevated creatine kinase (CK) levels, cerebral
white matter abnormalities and delayed motor mile-
stones with affected children usually not achieving
independent ambulation [10–12]. Feeding problems
and respiratory insufficiency are commonly reported
complications often requiring gastrostomy and/or arti-
ficial ventilator support [13, 14].
Other features such as cardiac involvement, a sen-
sory and motor demyelinating neuropathy, epilepsy
and mental retardation have been also documented in
some forms of LAMA2-RD [15–19].
An important diagnostic aspect is that skeletal mus-
cle biopsies from these patients have changes in
laminin-2 expression detected by immunohistochem-
ical (IHC) analysis [10]. However, there is a recent
report of a muscular dystrophy patient with appar-
ently normal laminin-2 IHC expression and having
mutations in LAMA2 gene [20].
Milder LAMA2-RD cases have been reported in
the past few years expanding the phenotypic spectrum
of the disease [21]. These patients have slower dis-
ease progression and acquire independent locomotion,
and are usually associated with a partial expression of
laminin-2 [22–26].
More than 375 distinct sequence variants (215
of them with known clinical relevance) have been
reported in the LSBD for LAMA2 gene (http://
www.dmd.nl/LAMA2, data accessed May 2014).
Pathogenic changes include small deletions/insertions
(34.9%), nonsense mutations (25.1%), changes affect-
ing splicing (25.6%) and also missense substitutions
(12.1%). In spite of the relevant amount of mutational
data available there is still a limited number (2.3%)
of large deletions and duplications reported in this
gene. The initial suspicion of a large LAMA2 dele-
tion (which was predicted to include exons 23 to 56)
was identified by protein truncation test in the work of
Pegoraro and collaborators [27]. The first fully char-
acterized large deletion in LAMA2, corresponds to an
out-of-frame deletion of exon 56 (c.7750-1713 7899-
2154del), which has been proven to be one of the most
frequent pathogenic variants detected in Portuguese
MDC1A patients [28].
One of the main objectives of this work was
to describe additional novel pathogenic deletions
and duplications associated with the LAMA2 gene,
identified in our cohort of CMD patients. More-
over, a systematic review of all cases with large
deletions/duplications reported in the literature and
mutation databases is presented. Our findings showed
that this type of mutation is fairly frequent and is under-
estimated in the literature, reinforcing the importance
to screen large deletions/duplications in LAMA2 gene
as part of the genetic diagnosis strategy.
MATERIAL AND METHODS
Patients
Over the last 10 years (2004-2014) our group per-
formed genetic studies in 94 CMD patients. Mutations
in genes related with CMD were identified in 68%
(n = 64) of these patients. The majority of these patients
have LAMA2 mutations (n = 52) and were referred for
molecular studies due to changes in muscle laminin-
2 detected by IHC analysis and/or compatible white
matter anomalies detected by magnetic resonance
imaging (MRI). In four patients of this cohort only
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one heterozygous mutation was detected upon LAMA2
genomic sequencing (described in Table 1). In these
patients we conducted screening of large deletions and
duplications in the LAMA2 gene. This research was
approved by the ethics committee from Hospital Centre
of Porto (CHP).
LAMA2 gene analysis
Genomic DNA (gDNA) was obtained from periph-
eral blood using the salting-out method [29]. LAMA2
gene sequencing was done according to [28], which
comprised all coding and adjacent intronic sequences
of LAMA2. Variants were described according to the
Human Genome Variation Society (HGVS) guidelines
for mutation nomenclature (version 2.0) [30] and using
the cDNA reference sequence with accession number
NM 000426.3.
MLPA analysis
Screening for deletions and duplications in LAMA2
gene was performed by multiplex ligation-dependent
probe application (MLPA) technique using two sets
of probe mixes (P391-A1 and P392-A1) from MRC-
Holland (Amsterdam, the Netherlands). These probe
mixes contain one probe for each exon of the gene
with the exception of exons 18, 44 and 48. Two probes
are present for exon 1, 2, 4 and 65 and three probes for
exon 56. Also, probemix P391 contains 9 reference
probes and P392 contains 8 reference probes detecting
different genomic regions. For the MLPA procedure,
150 ng gDNA was used for each patient and normal
control samples. Amplification products were subse-
quently separated by capillary electrophoresis on an
ABI 3130xl genetic analyser (Applied Biosystems,
Foster City, CA). Data analysis was conducted using
GeneMarker Software V1.5 (SoftGenetics LLC, State
College, PA). Population normalization method was
selected and data was plotted using probe ratio.
Southern blot
gDNA samples from patient P3, respective parents
and normal controls were digested with BglI (NewEng-
land Biolabs, Beverly, MA), resolved on a 0.7%
agarose gel and vacuum transferred to a GeneScreen
Plus membrane (Perkin Elmer, Waltham, MA) using a
saline method. A cDNA probe recognizing exons 2–4
was prepared using digoxigenin (DIG) DNA Labeling
Kit (Roche Applied Science, Indianapolis, IN, USA)
and incubated overnight using the Easy Hyb Buffer
(Roche Applied Science). The membrane was washed
at 60◦C in 1xSSC (Saline-Sodium Citrate)/0.1% SDS
(Sodium Dodecyl Sulfate) (Sigma-Aldrich, St. Louis,
MO) and twice in 0.5xSSC/0.1% SDS for 15 min
each. Subsequently, the membrane was prepared with
DIG Wash and Block Buffer Set (Roche Applied Sci-
ence), incubated with Anti-DIG-AP conjugate (Roche
Applied Science), and the DIG-labeled probe detected
with ready-to-use CDP-Star (Roche Applied Science).
LAMA2 cDNA analysis
cDNA studies were carried out in patient P2.
Total RNA was extracted from patient and con-
trol muscle biopsy samples using the PerfectPure
RNA Fibrous Tissue kit (5 PRIME, Germany)
and converted to cDNA using the High Capacity
cDNA Reverse Transcription kit (Applied Biosys-
tems, Foster City, CA). LAMA2 transcripts were
subjected to PCR amplification using specific primers
for the region corresponding to exons 27–32
(27F- 5′AAATTTCATGCGACAAAGCAGG; 32R-
5′GCTTGCAGCCGTCACACTTC). Resulting PCR
products were purified and sequenced as described
before.
Long-range PCR
The deletion breakpoints encompassing exon 3
(patient P3) and also exon 17 (patient P1) were
determined by amplification of gDNA using the BIO-
X-ACT Long DNA Polymerase kit (Bioline, Taunton,
MA). Specific primers were designed for each case;
complementary to intron 2 and exon 4, for the dele-
tion of exon 3 (2i-F:5′ACAAAGCCTGATGGAGG
GAAAC; 4-R:5′AAAGCGTTAGGCACTCCGTGTC)
and complementary to regions in exons 16 and 18,
for the deletion of exon 17 (16F:5′-TTGGTCATG
CGGAGTCCTG; 18R:5′ TGGCACGTTGGGC-
TAAAGC). Resolved PCR fragments were purified
using the QIAquick® Gel Extraction Kit (Qiagen,
Valencia, CA), and subsequently sequenced.
RESULTS
Novel large deletions and duplications
We previously reported a large deletion encompass-
ing exon 56 of the LAMA2 gene which is relatively
frequent in our laboratory patient cohort (present in
23% of our cases) [28]. This initial study suggested that
it is clinically relevant to screen this type of mutations
in CMD patients, and indirectly drove the development
of a MLPA commercial kit for LAMA2 gene (P391-A1
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and P392-A1 from MRC-Holland). As part of this work
we initially assessed the effectiveness of the MLPA kit
using previously genotyped DNA samples from our
patient cohort. Patients presenting homozygous and
heterozygous deletions encompassing LAMA2 exon 56
were tested. MLPA technique successfully detected
this mutation in homo- and heterozygous states (Sup-
plementary data I).
Four patients are presented in detail in this work;
P1 and P2 were previously described in the litera-
ture as P19 and P24, respectively in [28] while two
additional patients (P3 and P4) were more recently
referred for LAMA2 gene analysis. All of these patients
had incomplete molecular characterization: only one
heterozygous mutation was detected by genomic
sequencing and thus the molecular defect in the other
LAMA2 allele remained unknown. MLPA technique
was performed in DNA samples from these patients to
tentatively identify the second pathogenic mutation in
LAMA2.
Patient P1 presents a congenital muscular dystro-
phy (neonatal onset) and remained ambulatory until
the age of 17 years. In this patient a heterozygous
codon deletion (c.1798 1800del, p.Gly600del) was ini-
tially detected in LAMA2. MLPA analysis for this
patient revealed reduced hybridization of one probe
corresponding to exon 17 (Fig. 1A), compatible with
the presence of a heterozygous deletion involving
this exon. By reviewing genomic sequencing data we
excluded a potential sequence change which could
compromise the affinity of the MLPA probe. A long-
range PCR experiment was performed using primers
designed to bind regions presumably not involved
in the deletion (exons 16 and 18). Upon amplifica-
tion, two PCR products were detected in the patient,
whereas the experimental control had a single band
(data not shown). Sequencing across the deletion
breakpoint revealed that part of intron 16 is joined to
intron 17, corresponding to the loss of ∼5.3Kb that
spans exon 17 (Fig. 1B). This novel large mutation,
c.2322+259 2450+2037del, predictably causes frame-
shifting. DNA samples from the patient’s parents were
unavailable for study.
Patient P2 was referred for molecular study at
3 years of age having a typical MDC1A pheno-
type with absence of laminin-2 in IHC analysis
of muscle. The heterozygous nonsense mutation
c.3085C>T (p.Arg1029∗) was the only pathogenic
sequence change detected by sequencing the LAMA2
gene. A large heterozygous duplication encompass-
ing exons 28 and 29 was identified in patient P2
by MLPA (Fig. 2A). cDNA studies performed in the
Fig. 1. Results obtained for patient P1. (A) MLPA technique show-
ing reduction of one probe (0.5 peak ratio) corresponding to exon 17
of the LAMA2 gene. (B) Sequencing electropherogram of a fragment
(obtained from long-range PCR) that enabled the identification of
the deletion breakpoint, corresponding to the loss of ∼5.3 Kb.
patient revealed a normal transcript together with other
abnormal PCR products (Fig. 2B). These include one
out-of-frame transcript resulting from the contiguous
duplication of exons 28 and 29 (Fig. 2C).
Patient P3 with an MDC1A phenotype has a novel
nonsense mutation in exon 4 (c.497G>A, p.Trp166∗)
detected in a heterozygous and apparently homozy-
gous state, depending on the primer-pair used to study
this region (Fig. 3A). These ambiguous results led
us to suspect a possible deletion comprising at least
part of intron 3. The application of MLPA confirmed
this assumption, since a reduced amplification signal
was observed for the exon 3-specific probe (Fig. 3B).
For further characterization, and since no RNA was
available for study, we performed Southern-blotting
and hybridization using a cDNA probe that recog-
nizes exons 1 to 4. This experiment suggested that
the genomic deletion originates a new fragment of
approximately 6 Kb in the patient, that is absent
in the control (Fig. 3C). To delineate the deletion
endpoints several primers were tested to perform a
deletion-specific PCR. A 42931 bp deletion combined
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Fig. 2. Duplication identified in patient P2. (A) Increased signal for MLPA probes (peak ratios around 1.5) recognizing exon 28 (upper panel)
and exon 29 (lower panel). (B) cDNA analysis of LAMA2 transcripts revealed the presence of abnormal PCR products in the patient that were
not detected in the control. (C) Sequencing electropherogram of the cDNA PCR product (indicated by arrow) reveals the adjacent duplication
of exons 28 and 29. C- control; P- patient.
with the insertion of three nucleotides was identified,
annotated as c.284-4685 397-146delinsATA (Fig. 3D).
Compound heterozygosity for these two mutations was
confirmed by the analysis of patient’s parents.
Lastly, patient P4 has also an MDC1A phe-
notype but partial laminin-2 absence in muscle.
Besides one heterozygous 8 bp duplication in exon
13 (c.1854 1861dup) previously reported in the litera-
ture [9], we were able to identify a large heterozygous
deletion involving exons 3 to 10 by MLPA (Fig. 4).
This deletion is predicated to be out-of-frame. A more
extensive characterization was not possible since no
RNA sample was available for study. Compound het-
erozygosity was verified since each parent carried a
different mutation.
Novel point mutations in LAMA2
Fifty-two patients with LAMA2 mutations have been
characterized until now: 26 of which were previously
reported in 2008, and another two more recently in a
publication describing their atypical phenotype asso-
ciated with novel missense mutations [19]. In all cases
mutations have been identified in both disease alleles.
A list of 10 novel mutations is shown in supplemen-
tary data II. These include four nonsense mutations
(c.3520C>T, c.5263A>T, c.6501C>G e c.6979G>T),
four changes affecting splice sites (c.396+1G>T,
c.2450+4A>G, c.6708-1G>T and c.8988+1G>A), one
single nucleotide duplication (c.2350dupT) and a mis-
sense mutation (c.3235T>G, p.Cys1079Gly).
Reviewing large deletions and duplications in
LAMA2
As part of this work we reviewed all large dele-
tions and duplications reported in the literature
or in the locus specific database for the LAMA2
gene (http://www.lovd.nl/LAMA2, information last
accessed in May 2014). In addition to the muta-
tions presented in this publication, 12 different large
deletions and a single duplication were previously
described (Table 2).
LAMA2 large deletions (n = 15, reported in 35
patients) are apparently dispersed throughout the gene,
but two possible mutational “hotspots” may exist: i)
one includes exons 3 and 4 (5 different deletions) and
ii) in the 3’ region of the gene (from exons 56 to
65). The largest LAMA2 deletion, encompassing exons
23 to 56, was detected by the protein truncation test
[27] and comprehends more than half of the gene’s
coding regions. At least six different deletions affect
single exons and were confirmed by a second tech-
nique in order to exclude false positive results. The
majority of deletions are predicted to cause frame-
shifting (out-of-frame deletions). Still, only two cases
were further characterized at the cDNA level which
limits the accuracy of this data. Considering deletions
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Fig. 3. Characterization of a heterozygous deletion in patient P3. (A) The initial suspicion of a heterozygous deletion encompassing intron
3 derived from the genomic sequencing data. The nonsense mutation c.497G>A located in exon 4 was detected both in heterozygosity and
homozygosity depending upon the primers used. (B) Confirmation by MLPA, with reduced amplification signal for the exon 3 probe. (C)
Southern-blot followed by hybridization using a cDNA probe that recognizes exons 1 to 4, revealing a 6 Kb fragment in the patient and in his
mother, but not in the father nor the control. (D) Deletion breakpoint identified by deletion-specific PCR followed by sequencing. Sequencing
electropherogram revealed a 42.9 Kb deletion combined with the insertion of three nucleotides. C- control; F- father; M- mother; MW- molecular
weight marker; P3- patient 3.
predicted to be in-frame, all except one [31] were
reported in combination with a second truncating muta-
tion (causing a frame-shift or a nonsense mutation).
All of these patients have typical MDC1A phenotypes,
except the patient with the deletion of exons 41 to
48, which remains ambulant at the age of 10 years
(patient #6, reported by [32]). Six patients have been
described with large homozygous deletions which may
be explained by a higher frequency of a particular
mutation within the population (deletion of exon 56 in
Portugal and exon 4 deletion in Chinese patients) or due
to consanguinity in individual sporadic cases. Patients
with homozygous deletions are usually detected by
genomic sequencing, since the affected regions will
fail to amplify during PCR. Until now, no patients have
been reported with compound heterozygosity between
two different large rearrangements.
LAMA2 duplications are even rarer mutational
events; besides our report of a novel duplication
encompassing exons 28 and 29 detected in patient
P2, only one other heterozygous in-frame duplication
involving exons 5 to 12 has been documented in a
patient presenting muscular dystrophy [31]. However,
these authors did not identify a second mutation in
the patient, which might have explained an autosomal
recessive LAMA2-RD.
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Fig. 4. MLPA results for patient 4. Several LAMA2 probes with decreased peak ratios (0.5), corresponding to exons 3 to 10, compatible with a
large heterozygous deletion.
The frequency of large deletions and duplications
in LAMA2 may be estimated based on the two largest
patient cohorts reported and that employed quantitative
techniques: 18/104 alleles from our patient cohort of
52 patients and 17/86 alleles from the recent work of
Xiong and collaborators that studied 43 patients [32].
The overall frequency of these mutations is thus around
18.4% (35/190 alleles).
DISCUSSION
This work describes the detailed genetic charac-
terization of four patients with compatible features
with a MDC1A phenotype, but with only one het-
erozygous pathogenic sequence variant detected upon
complete LAMA2 sequencing. Three novel large dele-
tions in the LAMA2 gene and the first pathogenic large
duplication were successfully identified in this group
of patients, allowing a definitive molecular diagnosis,
carrier screening and prenatal diagnosis. Characteri-
zation of these mutations implied the use of a variety
of techniques such as long-range PCR, cDNA and
Southern-blot analysis. These methods are not gen-
erally used in the routine genetic diagnosis of this
disease, but are essential to obtain accurate genotype-
phenotype correlations.
Up to now reports of large deletions and duplica-
tions in LAMA2 are very rare; only three publications
have referred this type of mutation [28, 31, 32]. The
work of the Italian group included a more heteroge-
neous patient cohort and a broader technical approach.
An array-based comparative genomic hybridization
(array-CGH) developed to screen genes implicated in
neuromuscular diseases, enabled the identification of
several novel copy number variants (CNVs) includ-
ing two present in the LAMA2 gene [31]. Based on
the data from a total of 95 fully genotyped LAMA2-
RD patients, from two large cohorts, we estimate that
the frequency of large deletions and duplications in
LAMA2 may be as high as 18.4%. Considering this
relatively high frequency, it is important to include
screening techniques such as MLPA or array-CGH in
the molecular diagnostic work-up. Here, laboratories
should consider the variety of equipments required,
running costs and sensitivity of these two approaches
to screen this type of rearrangement. The presence of a
single heterozygous large deletion or duplication, espe-
cially when in-frame, should be carefully evaluated. It
is conceivable that the presence of a non-pathogenic
CNV in a CMD patient may not necessarily explain
the clinical phenotype.
Readers should also be aware that genomic sequenc-
ing is the technique with the highest sensitivity to
screen for LAMA2 mutations (>80%), especially in
CMD cases with laminin-2 deficiency. Our current
strategy for LAMA2 genetic analysis is sub-divided in
three tiers: i) the first level comprising a selected num-
ber of exons (namely: 3, 13, 22, 27, 33, 36, 54, 58,
and 61) corresponding to the genomic regions where
the majority of point mutations in our population are
located, together with the screening of exon 56 dele-
tion; ii) the second tier includes the remaining LAMA2
exons; and finally iii) MLPA analysis (two panels).
Until now, seventeen patients have been analyzed in
this manner. In 35% of patients both mutated alleles
were identified using tier 1, and in 82% at least one
heterozygous mutation was detected. We consider fea-
sible in our population to screen these LAMA2 regions
in patients with compatible features of CMD (such
as white matter changes in brain MRI), even before
performing a muscle biopsy.
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Large deletions and duplications detected in CMD
patients are not confined to LAMA2 gene; in
fact we have recently reported a patient with a
Fukuyama CMD caused by a multi-exonic duplica-
tion in FKTN (fukutin) [33]. There are additional
reports of other pathogenic CNVs in CMD genes,
such as: ISPD (isoprenoid synthase domain con-
taining) [34], LARGE (like-glycosyltransferase) [35,
36] and POMGNT1 [protein O-linked mannose N-
acetylglucosaminyltransferase 1 (beta 1,2-)] [37].
New mutation screening methods are currently
being developed based on next-generation sequencing
(NGS) technology, which will contribute to estab-
lish the genetic causes of hereditary myopathies that
remain unsolved. However, prior to its application,
it is important to exclude large deletions and dupli-
cations as a cause of these diseases. Bioinformatic
pipelines for NGS usually do not incorporate algo-
rithms that enable their automatic detection, but we
have previously shown that, when properly applied,
this technology can help delineate large genomic rear-
rangements [38].
In summary, we have reassessed the impact of large
deletions and duplications in LAMA2-RD and empha-
size the importance of including screening for these
rearrangements as part of the diagnostic strategy, espe-
cially in patients where a single heterozygous mutation
has been detected.
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